LOS ANGELES, CA / ACCESSWIRE / February 1, 2017 / Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Regulus Therapeutics Inc. ("Regulus" or the "Company") (RGLS) concerning possible violations of federal securities laws.
To get more information about this investigation, please click here, or contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
Regulus revealed that it was contacted by the U.S. Food and Drug Administration ("FDA") that its new drug against the chronic hepatitis C virus infection will be placed on clinical hold due to another incidence of jaundice.
On January 27, 2017, Regulus disclosed that the FDA would not remove the clinical hold on RG-101 until the agency confirms the last safety and efficacy information from continued clinical and pre-clinical studies.
When this information was revealed to the investing public, shares of Regulus fell sharply, causing investors serious harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
SOURCE: Lundin Law PC